Alpha 2.0
Login Register
» Authors » Alex Asiimwe

Alex Asiimwe

Explore the profile of Alex Asiimwe including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 34
Citations 226
Followers 0
Related Specialties
Urology
General Medicine
Pharmacology
Top 10 Co-Authors
Tina Raine-Bennett
Darios Getahun
Mary Anne Armstrong
Fagen Xie
Vicki Y Chiu
Theresa M Im
Michael J Fassett
Muhammad Imran Omar
Mieke Van Hemelrijck
Jiaxiao M Shi
Published In
Contraception
Nat Rev Urol
Pharmacoepidemiol Drug Saf
Am J Obstet Gynecol
BMJ Open
Affiliations
Soon will be listed here.
Recent Articles
1.
Linking clinical trial participants to their U.S. real-world data through tokenization: A practical guide
Eckrote M, Nielson C, Lu M, Alexander T, Gupta R, Low K, et al.
Contemp Clin Trials Commun . 2024 Sep; 41:101354. PMID: 39280783
In drug development, the use of real-world data (RWD) has augmented our understanding of patients' health care experiences and the effects of treatments beyond clinical trials. Although electronic health record...
2.
Clinical Characterization of Patients Diagnosed with Prostate Cancer and Undergoing Conservative Management: A PIONEER Analysis Based on Big Data
Gandaglia G, Pellegrino F, Golozar A, De Meulder B, Abbott T, Achtman A, et al.
Eur Urol . 2023 Jul; 85(5):457-465. PMID: 37414703
Background: Conservative management is an option for prostate cancer (PCa) patients either with the objective of delaying or even avoiding curative therapy, or to wait until palliative treatment is needed....
3.
Unanswered questions in prostate cancer - findings of an international multi-stakeholder consensus by the PIONEER consortium
Omar M, MacLennan S, Ribal M, Roobol M, Dimitropoulos K, Van den Broeck T, et al.
Nat Rev Urol . 2023 Apr; 20(8):494-501. PMID: 37012441
PIONEER is a European network of excellence for big data in prostate cancer consisting of 37 private and public stakeholders from 9 countries across Europe. Many progresses have been done...
4.
Demographic, Reproductive, and Medical Risk Factors for Intrauterine Device Expulsion
Anthony M, Zhou X, Schoendorf J, Reed S, Getahun D, Armstrong M, et al.
Obstet Gynecol . 2022 Nov; 140(6):1017-1030. PMID: 36357958
Objective: To explore to what extent intrauterine device (IUD) expulsion is associated with demographic and clinical risk factors. Methods: The APEX-IUD (Association of Perforation and Expulsion of IntraUterine Devices) study...
5.
How Well do Polygenic Risk Scores Identify Men at High Risk for Prostate Cancer? Systematic Review and Meta-Analysis
Siltari A, Lonnerbro R, Pang K, Shiranov K, Asiimwe A, Evans-Axelsson S, et al.
Clin Genitourin Cancer . 2022 Oct; 21(2):316.e1-316.e11. PMID: 36243664
Objectives: Genome-wide association studies have revealed over 200 genetic susceptibility loci for prostate cancer (PCa). By combining them, polygenic risk scores (PRS) can be generated to predict risk of PCa....
6.
Disparities in the Incidence of Ectopic Pregnancy in a Large Health Care System in California, 2010-2019
Raine-Bennett T, Fassett M, Chandra M, Armstrong M, Xie F, Shi J, et al.
Perm J . 2022 Aug; 26(3):61-68. PMID: 35939627
IntroductionEctopic pregnancy leads to reproductive health morbidity, including greater risk of another ectopic pregnancy, infertility, and, in rare cases, mortality. Information on trends in the incidence of ectopic pregnancy in...
7.
Time Trends and Treatment Pathways in Prescribing Individual Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation: An Observational Study of More than Three Million Patients from Europe and the United States
Vora P, Morgan Stewart H, Russell B, Asiimwe A, Brobert G
Int J Clin Pract . 2022 Jun; 2022:6707985. PMID: 35685531
Background: Data directly comparing trends in the use of different oral anticoagulants (OACs) among patients with atrial fibrillation (AF) from different countries are limited. We addressed this using a large-scale...
8.
Intrauterine device-related uterine perforation incidence and risk (APEX-IUD): a large multisite cohort study
Reed S, Zhou X, Ichikawa L, Gatz J, Peipert J, Armstrong M, et al.
Lancet . 2022 Jun; 399(10341):2103-2112. PMID: 35658995
Background: Reports of perforation risk related to intrauterine devices (IUDs) inserted immediately post partum and among non-post-partum individuals are scarce, and previous studies with only 12-month follow-ups underestimate the risk....
9.
Secondary Treatment for Men with Localized Prostate Cancer: A Pooled Analysis of PRIAS and ERSPC-Rotterdam Data within the PIONEER Data Platform
Beyer K, Straten V, Remmers S, MacLennan S, MacLennan S, Gandaglia G, et al.
J Pers Med . 2022 May; 12(5). PMID: 35629173
Introduction: Treatment choice for localized prostate cancer is complicated, as each treatment option comes with various pros and cons. It is well established that active surveillance (AS), may be ended...
10.
Association between intrauterine device type and risk of perforation and device expulsion: results from the Association of Perforation and Expulsion of Intrauterine Device study
Gatz J, Armstrong M, Postlethwaite D, Raine-Bennett T, Chillemi G, Alabaster A, et al.
Am J Obstet Gynecol . 2022 Apr; 227(1):57.e1-57.e13. PMID: 35395215
Background: Intrauterine devices, including levonorgestrel-releasing and copper devices, are highly effective long-acting reversible contraceptives. The potential risks associated with intrauterine devices are low and include uterine perforation and device expulsion....